(Q53943884)

English

Twelve-month results of an ongoing randomized trial comparing brimonidine tartrate 0.2% and timolol 0.5% given twice daily in patients with glaucoma or ocular hypertension. Brimonidine Study Group 2.

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

22 May 2018

http://europepmc.org/abstract/MED/9787370

Twelve-month results of an ongoing randomized trial comparing brimonidine tartrate 0.2% and timolol 0.5% given twice daily in patients with glaucoma or ocular hypertension. Brimonidine Study Group 2. (English)

1 reference

Europe PubMed Central

22 May 2018

http://europepmc.org/abstract/MED/9787370

0 references

1 reference

based on heuristic

inferred from title

author name string

R P LeBlanc

1

1 reference

Europe PubMed Central

22 May 2018

http://europepmc.org/abstract/MED/9787370

publication date

1 October 1998

1 reference

Europe PubMed Central

22 May 2018

http://europepmc.org/abstract/MED/9787370

1 reference

Europe PubMed Central

22 May 2018

http://europepmc.org/abstract/MED/9787370

105

1 reference

Europe PubMed Central

22 May 2018

http://europepmc.org/abstract/MED/9787370

10

1 reference

Europe PubMed Central

22 May 2018

http://europepmc.org/abstract/MED/9787370

1960-1967

1 reference

Europe PubMed Central

22 May 2018

http://europepmc.org/abstract/MED/9787370

Systemic effects of medications used to treat glaucoma

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2898%2991048-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Systemic drug interactions with topical glaucoma medications

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2898%2991048-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Systemic adverse reactions to glaucoma medications

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2898%2991048-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Topical beta-blocker therapy and central nervous system side effects. A preliminary study comparing betaxolol and timolol

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2898%2991048-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of brimonidine on aqueous humor dynamics in human eyes

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2898%2991048-X

7 January 2021

based on heuristic

inferred from DOI database lookup

The cardiovascular, pulmonary, and ocular hypotensive effects of 0.2% brimonidine

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2898%2991048-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical experience with brimonidine 0.2% and timolol 0.5% in glaucoma and ocular hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2898%2991048-X

7 January 2021

based on heuristic

inferred from DOI database lookup

A comparison of the safety and efficacy of twice daily brimonidine 0.2% versus betaxolol 0.25% in subjects with elevated intraocular pressure. The Brimonidine Study Group III

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2898%2991048-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Average Partial Association in Three-Way Contingency Tables: A Review and Discussion of Alternative Tests

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2898%2991048-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparison of apraclonidine and timolol in chronic open-angle glaucoma. A three-month study

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2898%2991048-X

7 January 2021

based on heuristic

inferred from DOI database lookup

The efficacy of apraclonidine as an adjunct to timolol therapy. Apraclonidine Adjunctive Therapy Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2898%2991048-X

7 January 2021

based on heuristic

inferred from DOI database lookup

A 90-day study of the efficacy and side effects of 0.25% and 0.5% apraclonidine vs 0.5% timolol. Apraclonidine Primary Therapy Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2898%2991048-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Long term effect of apraclonidine

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2898%2991048-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical experience with the long-term use of 1% apraclonidine. Incidence of allergic reactions

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2898%2991048-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Questions concerning the role of apraclonidine in the management of glaucoma

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2898%2991048-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Mechanisms of adrenergic agonist induced allergy bioactivation and antigen formation

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2898%2991048-X

7 January 2021

based on heuristic

inferred from DOI database lookup

A proposed mechanism for p-aminoclonidine allergenicity based on its relative oxidative lability

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2898%2991048-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0161-6420(98)91048-X

1 reference

Europe PubMed Central

22 May 2018

http://europepmc.org/abstract/MED/9787370

1 reference

Europe PubMed Central

22 May 2018

http://europepmc.org/abstract/MED/9787370

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q53943884&oldid=1400714379"